杭州迪安生物技术有限公司

What 杭州迪安生物技术有限公司 does

杭州迪安生物技术有限公司 (Dianbio), founded in 2014 in Hangzhou, is a wholly-owned subsidiary of 迪安诊断 (Diagno, Shenzhen-listed under ticker 300244) focused on the independent R&D, manufacture, and sale of in vitro diagnostic (IVD) reagents, instruments, and consumables. The company operates across two principal product categories: pathological diagnostics (digital slide scanning systems, fully automated immunohistochemistry stainers, liquid-based cytology preparation systems, and AI-assisted cervical cell screening software) and molecular diagnostics (HPV genotyping kits, real-time fluorescent PCR instruments, automated nucleic acid extraction systems, mNGS and tNGS infectious disease panels, and gene polymorphism detection kits such as MTHFR and ALDH2). Under the 金迪安 (Jin Dian) brand, Dianbio has secured more than ten NMPA Class III medical device registrations and holds over 100 software copyrights and patents spanning five proprietary instrument technology platforms.

The company serves hospital pathology, laboratory, and gynecology departments, third-party medical laboratories, CDCs, and grassroots healthcare institutions. Its go-to-market combines a direct enterprise sales team (with a 400 hotline for inquiries and orders) and the nationwide distribution network of its parent 迪安诊断. Pricing follows a non-public quote-based model customized to procurement volume and customer type. A key commercial milestone was winning third place in Group A of the 25-province HPV reagent centralized procurement alliance in December 2023, which secures multi-province public hospital volume.

The business model spans three revenue streams: IVD reagent sales (including HPV detection kits, liquid-based cytology reagents, and molecular diagnostic kits), diagnostic instrument sales (IHC stainers, PCR machines, nucleic acid extractors, digital slide scanners), and technical services plus after-sales support. The company is positioned as an integrated research-manufacturing-sales high-tech enterprise, with parent-company-backed data validation across hundreds of millions of cumulative test samples and recent expansion into tuberculosis active screening, oncology companion diagnostics (CLDN18.2), and AI-enabled digital pathology workflows.

Name

杭州迪安生物技术有限公司

Legal name

杭州迪安生物技术有限公司

Website

https://dianbio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

杭州迪安生物技术有限公司 (Dianbio) is a Hangzhou-based IVD subsidiary of Diagno (300244) that develops, manufactures, and sells in vitro diagnostic reagents, instruments, and consumables — spanning HPV/cervical cancer screening, molecular infectious disease diagnostics, and digital pathology — for hospitals, medical laboratories, and public health agencies across China.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

Keywords

• In vitro diagnostics
• Molecular diagnostics
• Pathological diagnostics
• IVD reagents
• Diagnostic instruments

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. 体外诊断试剂销售: 生产和销售体外诊断试剂盒，包括HPV检测试剂、液基细胞学检测试剂、分子诊断试剂盒等，主要面向医疗机构和检验中心
2. 诊断仪器设备销售: 销售全自动免疫组化染色仪、核酸提取纯化仪、实时荧光定量PCR仪、数字玻片扫描影像分析系统等仪器设备
3. 技术服务与售后支持: 提供一流的技术服务工程师、全面的试剂仪器维护体系、快速的客户服务响应机制和严格的质量反馈

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Hangzhou Dian Biotechnology Co., Ltd. develops, manufactures, and sells in vitro diagnostic (IVD) reagents, instruments, and consumables for clinical laboratories and healthcare institutions. Its portfolio spans two diagnostic categories: pathological diagnostics, including HPV testing kits, digital pathology slide scanners, and automated immunohistochemistry stainers; and molecular diagnostics, including PCR instruments, nucleic acid extraction systems, mNGS/tNGS infectious disease panels, and gene polymorphism detection kits.

Product overview

杭州迪安生物技术有限公司 (Dianbio) is a high-tech in vitro diagnostic (IVD) company established in 2014 as a subsidiary of Diagno (stock code: 300244). The company specializes in R&D, production, and sales of IVD reagents, instruments, and consumables. The product portfolio is organized into two main categories: pathological diagnostics (digital slide scanners, automated immunohistochemistry stainers, liquid-based cytology products, p16/Ki-67 double staining detection) and molecular diagnostics (HPV testing, PCR instruments, nucleic acid extraction systems, mNGS/tNGS infectious disease panels, gene polymorphism detection for MTHFR/ALDH2). Solutions offered include cervical cancer screening, digital pathology intelligent solutions, female reproductive tract infection solutions, and tuberculosis detection.

Differentiator

Problem solved

Functional benefit

Products and services

• HPV testing kits

Quantifiable outcome

• HPV检测累计超过2000万人份
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature12 records

Partnerships

One partnership is on record.

• 迪安诊断（股票代码：300244）coreStrategic or Co-development Partner · 1 January 2014迪安诊断是迪安生物的控股母公司，迪安生物成立于2014年，是迪安诊断的控股子公司。公司致力于体外诊断试剂及相关设备和耗材的自主研发、生产和销售。依托母公司的资源与渠道优势，实现研产销一体化发展。

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Hologic: Global IVD leader with the ThinPrep liquid-based cytology platform and Panther molecular diagnostics system — broad incumbent offering overlapping HPV, cytology, and molecular diagnostic capabilities that compete with Dianbio's cervical screening portfolio.
• Roche Diagnostics: Global IVD and molecular diagnostics leader with cobas PCR systems, HPV test menu, and digital pathology solutions — broad incumbent with overlapping HPV/molecular diagnostics and pathology capabilities competing against Dianbio in Chinese hospitals.

Direct peers

• Lepu Diagnostics: Chinese IVD company with broad product portfolio including chemiluminescence, PCR, POCT, and pathology reagents — comparable as a multi-platform Chinese IVD manufacturer serving hospital and clinical laboratory channels.
• BGI Genomics: China's leading genomics and molecular diagnostics company offering NGS-based infectious disease, HPV, NIPT, and pathology solutions — directly comparable to Dianbio's mNGS/tNGS panels and HPV genotyping products.
• Kingmed Diagnostics: China's largest third-party medical testing service network — comparable in clinical diagnostics scope, with sister-company Da An Gene representing an integrated manufacturing/services model similar to Dianbio's relationship with Dian Diagnostics.
• Autobio Diagnostics: Major Chinese IVD player with strong immunohistochemistry, chemiluminescence, and microbiology product lines — comparable in pathology/IVD reagents, particularly the IHC stainer and antibody business that overlaps Dianbio's pathology offerings.
• Sansure Biotech: Leading Chinese molecular diagnostics company specializing in infectious disease PCR kits, HPV testing, and NGS panels — comparable in molecular IVD focus, infectious disease menu, and channel model through hospitals and CDCs.
• Hybio Biomedical (Hyribio): Chinese IVD specialist focused on HPV molecular diagnostic kits, nucleic acid testing, and infectious disease reagents — directly comparable to Dianbio's HPV/cervical screening and molecular diagnostics portfolio.
• Da An Gene (Kingmed Holdings subsidiary): Chinese molecular IVD manufacturer with broad PCR and clinical reagent portfolio across HPV, infectious disease, and genetic testing — directly comparable in molecular diagnostics kit manufacturing and hospital sales motion.
• Snibe (Shenzhen New Industries Biomedical Engineering): Chinese IVD manufacturer specializing in chemiluminescence immunoassays and clinical chemistry analyzers — comparable in IVD instrumentation and reagent manufacturing serving hospital laboratories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E6%9D%AD%E5%B7%9E%E8%BF%AA%E5%AE%89%E7%94%9F%E7%89%A9%E6%8A%80%E6%9C%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 杭州迪安生物技术有限公司